This study will conduct a cluster randomized controlled trial to Evaluate whether the Intelligent Lipid Management Decision-support System can increase the proportion of patients 1-year target achievement (\<1.8 mmol/L) in acute ischemic stroke or TIA patients under Evolocumab treatment within 12 months post-intervention.
Age≥18 years as of the screening date;
Patients with non-cardioembolic ischemic stroke or TIA within 3 months prior to the screening date;
Prescribed Evolocumab at physician's discretion;
Signed informed consent.
Intracranial hemorrhagic diseases: such as cerebral hemorrhage, subarachnoid hemorrhage, etc.;
Patients confirmed by baseline head CT or MRI to have hemorrhage or other pathological brain diseases, such as vascular malformations, tumors, abscesses, or other common non-ischemic brain diseases (such as multiple sclerosis);
Silent cerebral infarction without signs and symptoms;
Participation in a clinical trial of another drug or device in the past 3 months or ongoing at the time of the screening date;